(8S,11S,14S)-N-(2,3-dihydroxypropyl)-14-[[2-[[(2R)-2-[[(2R)-2-[hexadecanoyl(methyl)amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]-methylamino]-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2,4,6(20),15(19),16-hexaene-8-carboxamide | 1415463-98-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (8S,11S,14S)-N-(2,3-dihydroxypropyl)-14-[[2-[[(2R)-2-[[(2R)-2-[hexadecanoyl(methyl)amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]-methylamino]-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2,4,6(20),15(19),16-hexaene-8-carboxamide
• CAS: 1415463-98-7
• 化学式: C₄₉H₇₅N₇O₁₂
• 分子量: 954.174
• InChiKey: ZCWXHWSJEOZHHQ-HAYWYJJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  68
• 可旋转键数：
  26
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  287
• 氢给体数：
  10
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  (8S,11S,14S)-N-(2,3-dihydroxypropyl)-14-[[2-[[(2R)-2-[[(2R)-2-[hexadecanoyl(methyl)amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]-methylamino]-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2,4,6(20),15(19),16-hexaene-8-carboxamide 在 sodium periodate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以60%的产率得到
  参考文献：
  名称：

  [EN] BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS
  [FR] ANALOGUES DE L'ARYLOMYCINE À SPECTRE ANTIBIOTIQUE LARGE

  摘要：

  提供了芳基霉素类似物，其中这些类似物可以具有广谱生物活性。已发现在一系列致病性细菌物种中，对天然产物芳基霉素的抗生素活性的抗性取决于细菌信号肽酶（SPases）的特定位置的单个氨基酸突变，其中脯氨酸残基的存在赋予了芳基霉素抗性。本文提供了可以克服该抗性并提供比芳基霉素A2等天然产物芳基霉素更广谱抗生素活性的芳基霉素类似物。提供了用于确定细菌菌株是否对窄谱芳基霉素抗生素敏感，或者是否需要广谱类似物进行治疗的方法。提供了用于治疗细菌感染的药物组合物和方法，以及芳基霉素类似物的合成方法。

  公开号：

  WO2013138187A1
• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 甲酸 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (8S,11S,14S)-N-(2,3-dihydroxypropyl)-14-[[2-[[(2R)-2-[[(2R)-2-[hexadecanoyl(methyl)amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]-methylamino]-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2,4,6(20),15(19),16-hexaene-8-carboxamide
  参考文献：
  名称：

  Efforts toward broadening the spectrum of arylomycin antibiotic activity

  摘要：

  New antibiotics are needed, and one source may be 'latent' antibiotics, natural products whose once broad-spectrum activity is currently limited by the evolution of resistance in nature. We have identified a potential class of latent antibiotics, the arylomycins, which are lipopeptides with a C-terminal macrocycle that target signal peptidase and whose spectrum is limited by a resistance-conferring mutation in many bacteria. Herein, we report the synthesis and evaluation of several arylomycin derivatives, and demonstrate that both C-terminal homologation with a glycyl aldehyde and addition of a positive charge to the macrocycle increase the activity and spectrum of the arylomycin scaffold. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.026

文献信息

• BROAD SPECTRUM ANTIBIOTICS
  申请人：Roberts Tucker Curran

  公开号：US20140249073A1

  公开（公告）日：2014-09-04

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
• BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS
  申请人：The Scripps Research Institute

  公开号：US20150045286A1

  公开（公告）日：2015-02-12

  Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.